Veracyte stock carries a Q2 revenue base of USD 150.32 million, up 15.5 percent year over year. Elev

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Lea la transcripción de la llamada de resultados de Veracyte Inc. R (12V.MU) Q1 FY2026 en Yahoo Finance para mantener su estrategia de inversión actualizada con toda la información más reciente.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Veracyte, Inc. recently presented retrospective ancillary Phase III NRG/RTOG 0815 trial data at the 2026 ASTRO meeting, showing that its Decipher Prostate Genomic Classifier can stratify which intermediate-risk prostate cancer patients benefit from adding short-term androgen deprivation therapy to dose-escalated radiation, with Level 1B1 prognostic and predictive evidence. The findings suggest Decipher could help physicians better balance treatment benefit against the metabolic and...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Among patients with intermediate/high Decipher scores, short-term hormone therapy with radiation was linked to an 8% absolute drop in 10-year distant metastasis.

First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026 SOUTH...

Seis presentaciones orales y dos carteles destacarán el valor pronóstico y predictivo de Decipher para identificar el riesgo de progresión de los pacientes y la probabilidad de beneficiarse de la intensificación del tratamiento.

Por qué invertir a largo plazo, especialmente si se compran ciertas acciones populares, podría generar enormes recompensas.

Seis presentaciones orales y dos carteles utilizan datos de ensayos y del mundo real para evaluar el riesgo de la enfermedad y el beneficio del tratamiento; ASTRO se reúne del 26 al 30 de septiembre en Boston.

Veracyte (VCYT) fue testigo de un salto en el precio de las acciones en la última sesión debido a un volumen de operaciones superior al promedio. La última tendencia en las revisiones de las estimaciones de ganancias para la acción no